News and Trends 28 Sep 2016 Little Biotechs manoeuvre to outfox Big Pharma in Immuno-Oncology Giants like BMS and GSK have been throwing all the money they can at developing immuno-oncological treatments. In twin deals, four smaller companies are forging new paths to cure cancer with the human immune response. A pair of agreements among immuno-oncology biotechs have been made in attempts to outflank big pharma competition. In Scandinavia, Orion will fund […] September 28, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2016 The Munich Biotech Mafia are at it again, raising €40M for an I/O Startup A new immuno-oncology startup has taken off with a booming round of VC fundraising. Details on its programs are sparse, but the company’s leadership is a veritable who’s who in German biotech, much like the PayPal Mafia. Immuno-oncology is surely an exciting field, but high-profile leadership is a huge bonus when it comes to attracting […] September 23, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2016 Evotec and Bayer renew their vows and take on Kidney Disease Evotec and Bayer are approaching the 4th anniversary of a successful partnership in endometriosis treatments that made it to clinical trials just last month. To celebrate, they’re starting a new 5-year partnership, this time concerning kidney disease. Evotec has a long list of top-level partners, including Roche, Sanofi, Boehringer Ingelheim and Takeda. After the successful outcome of […] September 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2016 German Biotech allies with Genentech in battle for Cancer Vaccine BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […] September 21, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2016 This European Biotech Initiative wants to remediate Contaminated Land It has been estimated that the impact of potentially polluting activities has affected around 3 million sites in Europe alone with great risk of adverse human health effects. As a result, there is considerable pressure to develop new innovative and cost-effective solutions to the problems posed by pollution. REMEDIATE ITN is making its approach. The project […] September 20, 2016 - 5 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2016 Novozymes moves on Microbes in recent Acquisition The world’s leading producer of enzymes is making moves in the microbial world. Novozymes just acquired Organobalance, a German biotech specializing in microbes. Novozymes is a pillar of the Danish biotech scene and the world’s leading enzyme manufacturer. In 2000, it spun out of Novo Nordisk under the supervision of the World’s Best CEO, and […] September 19, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2016 How Tech Transfer brings Science from the Bench to the Bedside There are so many exciting discoveries in scientific research that could be used to cure, feed and fuel the world, but there is a giant gulf between science and business. Tech transfer aims to bridge the gap! I interviewed a number of experts in the field to tell you how. Since the first modern biotechnology […] September 19, 2016 - 6 minutesmins - By Marie Godar Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2016 ‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease MorphoSys confirms that its antibody (bimagrumab) failed to meet the primary endpoint of a phase IIb/III trial for a muscle disease (sIBM), conducted by Novartis. Sad news for Novartis and MorphoSys. The two companies are developing bimagrumab for muscle diseases, as part of their ongoing collaboration, which has already resulted in 11 programmes. Bimagrumab was initially […] April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email